Observational studyThe Pan African medical journal2025
[Predictive factors of response to biotherapies in patients with rheumatoid arthritis: a cross-sectional observational study conducted in the Rheumatology Department of the Mohammed V Military Teaching Hospital, Rabat (Morocco)].
Observational study in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: therapeutic response to biologic agents in rheumatoid arthritis (RA) remains heterogeneous and is influenced by clinical, biological, and comorbid factors. This study aimed to identify the factors associated with a good clinical response to biologic therapy among RA patients followed in a North African context. Methods: a cross-sectional observational study was conducted at the Rheumatology Department of Mohammed V Military Teaching Hospital, Rabat, between January and December 2024. Sociodemographic, clinical, biological, and comorbidity data of patients treated with biologic agents were collected at the time of follow-up. Multivariable logistic regression analysis was performed to identify independent factors associated with a good clinical response according to the European League Against Rheumatism (EULAR) criteria. Results: a total of 153 patients were included, of whom 75.8% were women (mean age 57.5 ± 13.7 years). In multivariable analysis, anti-CCP antibody positivity (aOR = 3.15; 95% CI 1.62-6.14; P = 0.001) and initiation of biologic therapy within 1 year of diagnosis (aOR = 4.55; 95% CI 2.12-9.76; P < 0.001) were significantly associated with a better clinical response. Conversely, C-reactive protein > 15 mg/L (aOR = 0.29; 95% CI 0.14-0.63; P < 0.001) and diabetes (aOR = 0.33; 95% CI 0.15-0.74; P = 0.003) were associated with a poorer response. Conclusion: anti-CCP antibody positivity and early initiation of biologic therapy were associated with a better clinical response, whereas elevated CRP levels and diabetes were linked to an unfavourable therapeutic outcome. These findings highlight the importance of early and individualised management of RA, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.